The effects of curcumin and a modified curcumin formulation on serum Cholesteryl Ester Transfer Protein concentrations in patients with metabolic syndrome: A randomized, placebo-controlled clinical trial

Document Type: Original Research Article

Authors

1 Metabolic Syndrome Research Center, Department of Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Department of Nutrition, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Department of Modern Sciences and Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

4 Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

5 Department of Genetic, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

6 Institute for Science and Technology in Medicine, University of Keele, Thornburrow Drive, Stoke-on-Trent, Staffordshire ST4 7QB, UK

7 Biochemistry and Nutrition Research Center, Department of Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Abstract

Objective: Cholesteryl Ester Transfer Protein (CETP) mediates the transfer of cholesteryl ester from HDL-C to LDL-C and VLDL-C. The aim of the present trial was to evaluate the effect of curcumin and its modified formulation on serum CETP concentrations in patients with metabolic syndrome.
Materials and Methods: Participants were randomly allocated to one of three groups of 40 subjects receiving either unmodified curcumin or its phospholipid complex or placebo. Lipid profile and plasma CETP were measured at the start and sixweeksafter initiation of the treatment.The normality of data distribution was assessed by Kolmogorov-Smirnov test. Wilcoxon test was used for comparing the data before and after the intervention. The percent changes of CETP and biochemical factors among the three groups were compared using Kruskal-Wallis test.
Results: Serum CETP levels were not significantly altered among patients receiving curcumin.
Conclusion: Curcumin and its complex had no significant effect on serum CETP concentrations.

Keywords

Main Subjects


Aggarwal BB. 2010. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr, 30: 173-199.

Aggarwal BB, Kumar A, Aggarwal MS, Shishodia S. 2005. Curcumin derived from turmeric (Curcuma longa): a spice for all seasons. Phytopharmaceutic Cancer Chemoprev, 23: 351-387.

Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. 2008. Curcumin and cancer: an “old-age” disease with an “age-old” solution. Cancer lett, 267: 133-164.

Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P. 2011. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J, 32(11):1345-1361.

Curb JD, Abbott RD, Rodriguez BL, Masaki K, Chen R, Sharp DS, Tall AR. 2004. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res, 45: 948-953.

Davidson MH.  2012. HDL and CETP inhibition: will this DEFINE the future?.Curr Treat Options Cardiovasc Med, 14: 384-390.

Elseweidy MM, Younis NN, Elswefy SE, Abdallah FR, El-Dahmy SI, Elnagar G, Kassem HM. 2015. Atheroprotective potentials of curcuminoids against ginger extract in hypercholesterolaemic rabbits. Nat Prod Res, 29: 961-965.

Epstein J, Sanderson IR, MacDonald TT. 2010. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J nutr 103:1545-1557.

Fisher EA, Feig JE, Hewing B, Hazen SL, Smith JD. 2012. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol, 32: 2813-2820.

Ghatreh-Samani K, Farrokhi E, Hashemzadeh-Chaleshtori M, Nikookar M, Noormohammadian Z. 2012. Study of I405V polymorphism of cholesterol ester transfer protein gene in efficacy of statins on plasma level of high density lipoprotein cholesterol. J Shahrekord Univ Med Sci, 14: 1-10.

Julie S, Jurenka M. 2009. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa. A preclinical and clinical research. Altern Med Rev, 14: 277.

Kidd PM. 2009. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. Altern Med Rev, 14: 226-46.

Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. 2006. Multiple biological activities of curcumin: a short review. Life Sci,78: 2081-2087.

Marczylo TH, Verschoyle RD, Cooke DN, Morazzoni P, Steward WP, Gescher AJ. 2007. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol, 601: 71-7.

Rahimi HR, Mohammadpour AH, Dastani M, Jaafari MR, Abnous K, Mobarhan MG and Oskuee RK. 2016. The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial. Avicenna J Phytomed, 6: 567.

Ritchie S, Connell JM. 2007. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis, 17: 319-326.

Saberi-Karimian M, Parizadeh SMR, Ghayour-Mobarhan M, Moammeri SM, Fathi DB, Safarian H, Javandoost A, Ferns GA, Sahebkar A, Ahmadinejad M. 2018.  Evaluation of the effects of curcumin in patients with metabolic syndrome. Comp Clin Pathol, 2018: 1-9.

Sahebkar A. 2014. Curcuminoids for the management of hypertriglyceridaemi. Nat Rev Cardiol, 11: 123-123.

Sandhofer A, Kaser S, Ritsch A, Laimer M, Engl J, Paulweber B, Patsch JR, Ebenbichler CF. 2006. Cholesteryl ester transfer protein in metabolic syndrome. Obesity, 14: 812-818.

Shehzad A, Lee Y. 2010. Curcumin: Multiple molecular targets mediate multiple pharmacological actions: A review. Drugs Fut, 35: 113.

Shin SK, Ha TY, McGregor RA, Choi MS. 2011. Long‐term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism. MolNutr Food Res, 55:1829- 1840.

Tavil Y, Sen N, Yazıc HU, Hızal F, Abacı A, Cengel A. 2007. Cengel, Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease. Thromb Res, 120: 245-250.

Upadhyay S, Dixit M. 2015. Role of polyphenols and other phytochemicals on molecular signaling. Oxid Med Cell Longev, 2015.